2024-04-30 カリフォルニア大学サンタバーバラ校(UCSB)
<関連情報>
- https://news.ucsb.edu/2024/021452/researchers-reveal-new-approach-treating-degenerative-diseases
- https://www.sciencedirect.com/science/article/pii/S1534580724002284
Zn2+輸送体ZIP7は小胞体関連タンパク質の分解を促進し、ショウジョウバエの神経変性を防ぐ The Zn2+ transporter ZIP7 enhances endoplasmic-reticulum-associated protein degradation and prevents neurodegeneration in Drosophila
Xiaoran Guo, Morgan Mutch, Alba Yurani Torres, Maddalena Nano, Nishi Rauth, Jacob Harwood, Drew McDonald, Zijing Chen, Craig Montell, Wei Dai, Denise J. Montell
Developmental Cell Published: April 25, 2024
DOI:https://doi.org/10.1016/j.devcel.2024.04.003
Highlights
•The ER-localized Zn2+ transporter ZIP7 promotes ER-associated degradation (ERAD)
•ZIP7 provides rate-limiting Zn2+ to degrade proteins that misfold in the ER
•ZIP7 enhances protein deubiquitination by the Zn2+ metalloproteinase Rpn11
•ZIP7 overexpression prevents blindness in a Drosophila model of neurodegeneration
Summary
Proteotoxic stress drives numerous degenerative diseases. Cells initially adapt to misfolded proteins by activating the unfolded protein response (UPR), including endoplasmic-reticulum-associated protein degradation (ERAD). However, persistent stress triggers apoptosis. Enhancing ERAD is a promising therapeutic approach for protein misfolding diseases. The ER-localized Zn2+ transporter ZIP7 is conserved from plants to humans and required for intestinal self-renewal, Notch signaling, cell motility, and survival. However, a unifying mechanism underlying these diverse phenotypes was unknown. In studying Drosophila border cell migration, we discovered that ZIP7-mediated Zn2+ transport enhances the obligatory deubiquitination of proteins by the Rpn11 Zn2+ metalloproteinase in the proteasome lid. In human cells, ZIP7 and Zn2+ are limiting for deubiquitination. In a Drosophila model of neurodegeneration caused by misfolded rhodopsin (Rh1), ZIP7 overexpression degrades misfolded Rh1 and rescues photoreceptor viability and fly vision. Thus, ZIP7-mediated Zn2+ transport is a previously unknown, rate-limiting step for ERAD in vivo with therapeutic potential in protein misfolding diseases.